Shanghai Pharmaceuticals: Generic Equivalence Evaluation of Solterol Hydrochloride Tablets

Shanghai Pharmaceuticals recently announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the Hydrochloride Sotalol Tablets. The drug has passed the evaluation of generic drug quality and efficacy consistency. As of the date of this announcement, the company has invested approximately 4.6 million RMB in research and development expenses for the consistency evaluation of this drug. According to IQVIA database, the amount of Hydrochloride Sotalol Tablets purchased by mainland China hospitals in 2024 is 33.117 million RMB.